NCT05790304View on ClinicalTrials.gov

Study to Investigate Hepatic Impairment on PK, Safety, Tolerability of Camizestrant in Post-Menopausal Female Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

February 20, 2023

Primary Completion Date

February 22, 2024

Study Completion Date

February 22, 2024

Conditions
Hepatic Impairment
Interventions
DRUG

Camizestrant

Camizestrant 75 mg tablets. Experimental drug.

Trial Locations (4)

1612

Research Site, Sofia

78215

Research Site, San Antonio

78229

Research Site, San Antonio

831 01

Research Site, Bratislava

Sponsors

Lead Sponsor

AstraZeneca
All Listed Sponsors
lead

AstraZeneca

INDUSTRY